Hikal Ltd. (BSE: 524735) is a Navi Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹2,657 Cr, it ranks #1,101 by market cap among the 6,137 Indian listed companies on FinBizNet, and #35 of 86 in Medicinal Chemicals and Botanical Products. At ₹193.65 (as of 25 Oct 2026), the share price is 25.8% below its 52-week high of ₹261.00 and 32.4% above its 52-week low of ₹146.25. The share price is down 20.0% over one year and down 10.9% over three months.
| Current Price | ₹193.65 |
|---|---|
| Market Cap | ₹2,657 Cr |
| BSE Code | 524735 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | -55.2 |
| Return on Equity | -3.97% |
| Return on Assets | 1.45% |
| 52-Week Range | ₹146.25 – ₹261.00 |
| 1-Year Price Change | -20.0% |
| 3-Month Price Change | -10.9% |
| Beta (1Y) | 0.94 |
| Dividend Yield | 0.37% |
| Headquarters | Navi Mumbai, Maharashtra |
| Website | www.hikal.com |
| Revenue | ₹403 Cr |
|---|---|
| Net Profit | ₹-7 Cr |
| Net Margin | -1.8% |
| EPS (Basic) | ₹-0.60 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. It operates through two segments, Pharmaceuticals and Crop Protection. The company also manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it offers solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. Further, the company provides anti-convulsant, anti-inflammatory, analgesic, Anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, Anti-viral, anti-hypertensive, and Haemorheologic; animal health products, such as
1. Crop Protection Products-This segment manufactures pesticides and herbicides. It is also involved in custom synthesis and custom manufacturing of intermediates and active ingredients. 2. Pharmaceuticals-This segment produces in active pharmaceutical ingredients. It is also involved in contract research activities. 3. Corporate / Unallocated Segment-0 4. Pharmaceuticals - Overseas Operation-This segment manufactures and supplies active pharmaceutical ingredients in India. It also engages in the contract research, custom synthesis, and custom manufacture of active pharmaceutical ingredients.
1. Pharmaceuticals-59.6% 2. Crop Protection-40.4%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Hikal Ltd. | ₹2,657 Cr | -55.2 | -3.97% | ₹403 Cr | -20.0% |
Listed by market capitalisation. Ratios are shown for context only.
Hikal Ltd. is trading at ₹193.65, with a market capitalisation of ₹2,657 Cr.
Hikal Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Hikal Ltd. has a P/E of -55.2 and a return on equity of -3.97%.
Hikal Ltd. is listed on the BSE under the scrip code 524735.
Hikal Ltd.'s share price is down 20.0% over one year and down 10.9% over three months. Its 52-week range is ₹146.25 to ₹261.00.
In Q1 FY27, Hikal Ltd. reported revenue of ₹403 Cr and net profit of ₹-7 Cr, with basic EPS of ₹-0.6 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.